HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $63 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and maintained a price target of $63.
September 13, 2023 | 10:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mirum Pharmaceuticals has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $63.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Mirum Pharmaceuticals. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100